Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33399560

about

Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis Recent advances in multidisciplinary management of hepatocellular carcinoma Management of hepatocellular carcinoma with portal vein thrombosis Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future Current systemic treatment of hepatocellular carcinoma: A review of the literature Minimally invasive image-guided therapies for hepatocellular carcinoma 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.Multidisciplinary management of hepatocellular carcinoma in clinical practice.Evolving role of Sorafenib in the management of hepatocellular carcinoma.Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases New progress of non-surgical treatments for hepatocellular carcinoma.Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma.The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives.Clinical trials in hepatocellular carcinoma: an update.Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).

P2860

Q24619987-0564D7FD-C229-483A-A057-B24F6CCD919A Q26749847-F73FE988-686A-46E8-BCE0-6437A5F69394 Q26863748-B8D0C713-0853-4C97-BDC8-2AEA6698719B Q26996578-577CF80F-D8B1-4CF5-BF57-CCB6EAD0BC89 Q27007847-FD1B5B8B-C56C-4C92-AB30-F1F45F02FEFD Q27013055-19DEFABD-832F-4E19-AE8D-CD7721F9B507 Q27026036-A88552E2-4B9A-447E-A3D3-70E9B703B26D Q28079027-6B31B347-6B94-4D57-B4DD-F7A2BB7D81D9 Q28392783-8AAB4CD9-8B9A-4C4C-A59C-F0FFECC7F2D7 Q28394414-70C94AE0-387C-4CB5-990A-CFA530FD8ACD Q33590407-06EB434D-D8A3-41CA-B802-8E32E69FD885 Q33666679-BA9FCC50-FB91-4275-BF82-C295E8C19459 Q33779864-B9350CA7-9792-4EF7-AD19-EC194B61C2DD Q33914180-1198AD73-4930-48B4-8E09-53B5E6A22E9E Q33944599-467840EE-0D6D-42FE-B4AA-665FD5E9DE89 Q34575821-A5412998-9C2F-4C0E-9F3A-5166F3AAB6A1 Q34647076-A11B1B1C-35FA-4DA8-855B-B3C3EF501B4C Q34658445-492FFFAC-DB27-432B-B1DF-561B1823D007 Q34770140-90E8A15B-85F1-4E99-A36A-DC22B7A861D9 Q34991643-58B1653B-7425-403E-A6E8-8A7AA4811336 Q35025403-B0DB9A42-4D63-4745-B313-2C3E885D157D Q35091836-0A809A3D-A398-48DF-B551-468E860CCBD4 Q35231826-CF031900-0457-4F2B-9683-E56EB976E6D7 Q35867676-B1281AB3-B098-4DC1-AEBB-D051DC29FDBE Q36140832-299239E2-5286-43F5-90E7-6CC398AE0FD3 Q36270115-C432F121-874F-4C5E-8960-06883F8DACCD Q36272834-9306529D-327D-4EE5-B4E3-CD453CA03C9C Q36325065-D70056CE-9B29-46B4-8AB8-F20A2C16B3F5 Q36371605-198F78C6-661A-445B-B021-0F3AD29A3D2A Q36414519-0294B560-1792-4305-AE87-C5E574360672 Q36415924-DFA0C57B-1380-4E96-B183-589A43504A67 Q36500323-230BF818-7F68-46DD-A8D0-7343D15A44D6 Q36528048-CD699570-FC5C-4AE4-85BF-983F50763F66 Q37031712-7F119C6E-69AD-4100-8A1F-DFA807F6183C Q37435638-276C6D4F-6A3F-442B-9E05-1F13F9D9B82E Q37581359-7A0DA464-1D56-4233-8735-68CF5EC2E367 Q37687559-733FE07F-4EA2-44A0-95CA-CDAFC905345A Q37696388-8D55BF20-C8A2-4F2F-85FF-43D21D974D7E Q37708002-8325B408-A0A5-44D9-89E5-0E6B238B414E Q38075142-09E907A1-E364-4CF9-8372-CD06FAF08E58

P2860

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33399560

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase II study of concurrent t ...... able hepatocellular carcinoma.

@ast

Phase II study of concurrent t ...... able hepatocellular carcinoma.

@en

type

label

Phase II study of concurrent t ...... able hepatocellular carcinoma.

@ast

Phase II study of concurrent t ...... able hepatocellular carcinoma.

@en

prefLabel

Phase II study of concurrent t ...... able hepatocellular carcinoma.

@ast

Phase II study of concurrent t ...... able hepatocellular carcinoma.

@en

P1433

Q33399560-D721548F-BAE2-48E3-B4E8-4984DBB841C5

P1476

Q33399560-622CAFEB-BB2B-41BA-8049-C69F2CD3E74C

P2093

Q33399560-117060F7-6AD7-4194-B2FE-3FD669B8E1BD

Q33399560-179BAA23-8750-41AB-8EAC-D9CE60A843BA

Q33399560-74BCFA06-DAB0-4AFE-9BED-2AF2194698B8

Q33399560-91DEBBD6-8079-4F69-A67D-A7B2DE37E5DA

Q33399560-9D0BEAB5-A4D8-4397-B1F0-5B1500DDBD7E

Q33399560-F5813896-15DA-4D3F-84ED-2C2FA82CD322

Q33399560-FB4CE949-D596-463A-8DFB-CA4B5C37A3D6

P304

Q33399560-02D2E45E-0611-4992-B975-AC4E607B0A0C

P31

Q33399560-3190586C-663E-48B3-96DA-EFB592741605

P356

Q33399560-335E3ECC-097C-454D-8A5B-70803F684593

P433

Q33399560-4A342E83-5801-472A-9DAF-672298DFF408

P478

Q33399560-C7068F89-DEE8-4236-8BDA-342D2CA361C1

P50

Q33399560-D1D721E0-6291-4CAB-9348-6B7688D612A1

P577

Q33399560-00FF8DE1-B147-4131-B91D-CF6C11BB4C3D

P698

Q33399560-17F54894-1676-4F21-9A5D-21CECD7E9F8D

P356

J.JHEP.2012.01.006

P1433

Journal of Hepatology

P1476

Phase II study of concurrent t ...... able hepatocellular carcinoma.

@en

P2093

Byung-Ho Nam

http://www.w3.org/2001/XMLSchema#string

Hwi Young Kim

http://www.w3.org/2001/XMLSchema#string

Hyun Beom Kim

http://www.w3.org/2001/XMLSchema#string

Joong-Won Park

http://www.w3.org/2001/XMLSchema#string

Sang Myung Woo

http://www.w3.org/2001/XMLSchema#string

Sangbu An

http://www.w3.org/2001/XMLSchema#string

Young Hwan Koh

http://www.w3.org/2001/XMLSchema#string

P304

1336-1342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JHEP.2012.01.006

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22314421

http://www.w3.org/2001/XMLSchema#string